目的分析总结肝癌肝移植后复发患者应用索拉非尼及介入栓塞治疗方案的价值。方法将204例肝癌接受肝移植治疗后复发的患者随机分为研究组和对照组各102例。对照组采用索拉非尼治疗,研究组采用索拉非尼联合介入栓塞治疗。对比2组接受治疗前、治疗1个月及治疗3个月时血清Foxp3+Treg细胞占淋巴细胞百分率(Foxp3+Treg%)变化情况,并对2组短期预后进行评价。结果接受治疗前2组Foxp3+Treg%比较差异无统计学意义(P<0.05)。治疗1、3个月后,2组Foxp3 Treg%水平均高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0.05)。随访1年,研究组肿瘤复发率、肿瘤转移率及病死率均明显低于对照组,差异均有统计学意义(P<0.05)。结论索拉非尼联合介入栓塞治疗方案不仅可有效的提高肝癌肝移植术后Foxp3+Treg%,同时对患者的短期预后同样有着一定的改善作用。 Objective To analyze the value of sorafenib and interventional embolization in patients with recurrent liver cancer after liver transplantation. Methods Totally 204 patients with recurrent liver cancer after liver transplantation were randomly divided into study group and control group with 102 cases each. The control group was treated with sorafenib, and the study group was treated with sorafenib combined with interventional embolization. The changes of Foxp3 + Treg cell percentage (Foxp3 + Treg%) in two groups before treatment, one month after treatment and three months after treatment were compared, and the short-term prognosis was evaluated. Results There was no significant difference in Foxp3 + Treg% between the two groups before treatment (P <0.05). After 1 and 3 months of treatment, the levels of Foxp3 Treg% in both groups were significantly higher than those before treatment, and the difference between the two groups was statistically significant (P <0.05). The follow-up of 1 year, the study group tumor recurrence rate, tumor metastasis rate and mortality were significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Sorafenib combined with interventional embolization not only can effectively improve the Foxp3 + Treg% of liver cancer after liver transplantation, but also has certain improvement effect on the short-term prognosis of patients.